1. Ahmadibeni, Y., Parang, K. Solid-supported reagents for synthesis of nucleoside monothiophosphates, dithiodiphosphates, and trithiotriphosphates. Curr. Protoc. Nucleic Acid Chem., in press.

2. Agarwal, H. K., Doncel, G., Parang, K. Synthesis and anti-HIV activities of phosphate triester derivatives of 3′-fluoro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine. Tetrahedron Lett. (2008) 49, 4905-4907.

3. Ye, G., Tiwari, R., Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr. Opin. Investig. Drugs (2008) 9, 605-613.

4. Ahmadibeni, Y., Parang, K. Solid-supported diphosphitylating and triphosphitylating reagents for nucleoside modification. Curr. Protoc. Nucleic Acid Chem. (2008) Chapter 13:Unit13.8.

5. Penugonda, S., Kumar, A., Agarwal, H. K., Parang, K., Mehvar, R. Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: Effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates. J. Pharm. Sci. (2008) 97, 2649-2664.

6. Ahmadibeni, Y., Parang, K. Solid-phase synthesis of symmetrical 5’,5’-dinucleoside mono-, di-, tri-, and tetraphosphodiesters. Org. Lett. (2007) 9, 4483-4486.

7. Bhandari, R., Saiardi, A., Ahmadibeni, Y., Snowman, A. M., Resnick, A. C., Kristiansen, T. Z., Molina, H., Pandey, A., Werner, Jr. J. K., Juluri, K. R., Xu, Y., Prestwich, G. D., Parang, K., Snyder, S. H. Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational event. Proc. Nat. Acad. Sci. U.S.A. (2007) 104, 15305-15310.

8. Chimalakonda, C., Agarwal, H., Kumar, A., Parang, K., Mehvar, R. Synthesis, analysis, in vitro characterization, and in vivo disposition of a lamivudine-dextran conjugate for selective antiviral delivery to the liver. Bioconjugate Chem. (2007) 18, 2097-2108.

9. Ye, G., Nam, N. H., Saleh, A., Kumar, A., Sun, G., Shenoy,  D. B., Amiji, M. M., Parang, K. Cellular delivery of phosphopeptides with tripodal peptide analogues. J. Med. Chem. (2007) 50, 3604-3617.

10. Ahmadibeni, Y., Hanley, M., White, M., Ayrapetov, M., Lin, X., Sun, G., Parang, K. Metal-binding properties of a dicysteine-containing motif in protein tyrosine kinases. ChemBioChem (2007) 8, 1592-1605.

11. Carballeira, N. M., O’Neil, R., Parang, K. Synthesis and antifungal properties of alpha-methoxy and alpha-hydroxyl substituted 4-thiatetradecanoic acids. Chem. Phys. Lipids (2007) 150, 82-88.

12. Ahmadibeni, Y., Parang, K., Synthesis and evaluation of oligodeoxynucleotides containing diphosphodiester internucleotide linkages. Angew. Chem. Int. Ed. (2007) 46, 4739-4743.

13. Kumar, A., Wang, Y., Lin, X., Sun, G., Parang, K. Synthesis and evaluation of 3-phenylpyrazolopyrimidine-peptide conjugates as Src tyrosine kinase inhibitors. ChemMedChem (2007) 2, 1346-1360.

14. Agarwal, H. K., Parang, K. Application of solid-phase chemistry for the synthesis of 3’-fluoro-3’-deoxythymidine. Nucleosides, Nucleotides& Nucleic Acids (2007) 26, 317-322.

15. Gu, X., Wang, Y., Kumar, A., Ye, G., Parang, K., Sun, G. Design and evaluation of hydroxamate derivatives as metal-mediated inhibitors of a protein tyrosine kinase. J. Med. Chem. (2006) 49, 7532-7539.

16. Kumar, A., Ye, G., Wang, Y., Lin, X., Sun, G., Parang, K. Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogs of CIYKYY as Src tyrosine kinase inhibitors. J. Med. Chem. (2006) 49, 3395-3401.

17. Carballeira, N. M., Sanabria, D., Cruz, C., Parang, K., Wan, B., Franzblau, S. 2,6-Hexadecadiynoic acid and 2,6-nondecadiynoic acid – Novel synthesized acetylenic fatty acids as potent antifungal agents. Lipids (2006) 41, 507-511.

18. Ahmadibeni, Y., Parang, K. “Application of a solid-phase β-triphosphitylating reagent in the synthesis of nucleoside β-triphosphates. J. Org. Chem. (2006) 71, 5837-5839.

19. Ahmadibeni, Y., Parang, K. Solid-phase synthesis of dinucleoside and nucleoside-carbohydrate phosphodiesters and thiophosphodiesters. J. Org. Chem. (2006) 71, 6693-6696.

20. Lee, S., Ayrapetov, M. K., Kemble, D., Parang, K., Sun, G. Docking-based substrate recognition by the catalytic domain of a protein tyrosine kinase, the C-terminal Src kinase. J. Biol. Chem. (2006) 281, 8183-8189.

21. Lin, X., Wang, Y., Ahmadibeni, Y., Parang, K., Sun, G. Structural basis for domain-domain communication in a protein tyrosine kinase, Csk. J. Mol. Biol. (2006) 357, 1263-1273.

22. Ayrapetov, M. K., Wang, Y.-H., Xiaofeng, L., Gu X., Parang, K., Sun G. Conformational basis for SH2-pTYR527 binding in SRC inactivation. J. Biol. Chem. (2006) 281, 23776-23784.

23. Kumar, A., Ye, G., Ahmadibeni, Y., Parang, K. Synthesis of polymer-bound 4-acetoxy-3-phenylbenzaldehyde derivatives: Applications in solid-phase organic synthesis. J. Org. Chem. (2006) 71, 7915-7918.

24. Parang K. Editor. Novel approaches in designing anti-HIV microbicides and anti-HIV Agents. Curr. Pharm. Des. (2005) 11, 123 pp.

25. Ahmadibeni Y., Parang K. Selective diphosphorylation, dithiodiphosphorylation, triphosphorylation, and trithiotriphosphorylation of unprotected carbohydrates and nucleosides. Org. Lett. (2005) 7, 5589-5592.

26. Parang K., Sun G. Recent advances in the discovery of Src kinases inhibitors. Expert Opin. Ther. Patents (2005) 15, 1183-1207.

27. Ye G., Ayrapetov M., Nam N. H., Sun G., Parang K. Solid-phase binding assays of peptides using EGFP-Src SH2 domain fusion protein and biotinylated Src SH2 domain. Bioorg. Med. Chem. Lett. (2005) 15, 4994-4997.

28. Carballeira N. M., O’Neill R., Parang K. Total synthesis and further scrunity of the in vitro antifungal activity of 6-nonadecynoic acid. Arch. Pharm.-Pharm. Med. Chem. (2005) 338, 441-443.

29. Ayrapetov M. K., Nam N. H., Ye G. Kumar A., Parang K., Sun G. Functional diversity of Csk, Chk, and Src SH2 domains due to a single residue variation. J. Biol. Chem. (2005) 280, 25780-25787.

30.  Parang K., Nam N. H. Sardari S. Preparation of azole monosaccharide as antifungal agents. PCT Int. Appl. 006860 (2005) 62 pp.

31. Ahmadibeni Y., Parang K. Polymer-bound oxathiaphospholane: A solid-phase reagent for regioselective monothiophosphorylation and monophosphorylation of unprotected nucleosides and carbohydrates. Org. Lett. (2005) 7, 1955-1958.

32. Carballeira N. M., O’Neill, R., Parang K. Racemic and optically active 2-methoxy-4-oxatetradecanoic acids: Novel synthetic fatty acids with selective antifungal properties. Chem. Phys. Lipids (2005) 136, 47-54.

33. Parang, K.; Sun, G.; Kumar, A.; Nguyen, N. H.; Wang, Y.-H.; Ye, G. Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents. PCT Int. Appl. WO 117932 (2005), 74 pp.

34. Hines A. C., Parang K., Kohanski R. A., Hubbard S. R., Cole P. A. Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: Molecular yardsticks for analyzing catalytic mechanism and inhibitor design. Bioorg. Chem. (2005) 33, 285-297.

35. Lin X., Ayrapetov M. K., Lee S., Parang K., Sun G. Probing the communication between the regulatory and catalytic domains of a protein tyrosine kinase, Csk. Biochemistry (2005) 44, 1561-1567.

36. Ahmadibeni Y., Parang K. Solid-phase reagents for selective monophosphorylation of carbohydrates and nucleosides. J. Org. Chem. (2005) 70, 1100-1103.

37. Parang K., Sun G. Protein kinase inhibitors in drug discovery. Drug Discovery Handbook, 2005, Wiley-Interscience, New Jersey, Ed. Gad, S. C. 1191-1257.

38. Parang K., Sun G. Design strategies for protein kinases inhibitors. Current Opinions In Drug Discovery (2004) 7, 630-638.

39. Nam N. H., Lee S., Ye G., Sun G., Parang K. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorg. Med. Chem. (2004) 12, 5753-5766.

40. Nam N. H., Sardari S., Selecky M., Parang K. Carboxylic acids and phosphate ester derivatives of fluconazole: synthesis and antifungal activities. Bioorg. Med. Chem. (2004) 12, 6255-6269.

41. Schmidt B., Jiricek J., Titz A., Ye G., Parang K. Copper dipicolinates as peptidomimetic ligands for the Src SH2 domain. Bioorg. Med. Chem. Lett. (2004) 14, 4203-4206.

42. Nam N. H., Pitts R., Sun G., Sardari S., Tiemo A., Xie M., Yan B., Parang K. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Bioorg. Med. Chem. (2004) 12, 779-787.

43. Nam N.-H., Ye G., Sun G., Parang K. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. J. Med. Chem. (2004) 47, 3131-3141.

44. Carballeira N. M., Ortiz D., Parang K., Sardari S. Total synthesis and in vitro antifungal activity of 2-methoxytetradecanoic acid. Arch. Pharm.-Pharm. Med. Chem. (2004) 337, 152-155.

45. Force T., Kuida K., Parang K., Kyriakis J. M. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation (2004) 109, 1196-1205.

46. Lee S., Lin X., Nam N. H., Parang K., Sun G. Determination of the substrate-docking site of protein tyrosine kinase Csk. Proc. Nat. Acad. Sci. U.S.A. (2003) 100, 14707-14712.

47. Sardari S., Pourmorad F., Tiemo A., Nam H., Parang K. Protein kinases and their modulation in the central nervous system. Current Medicinal Chemistry-CNS (2003) 3, 341-364.

48. Nam N. H., Sardari S., Parang K. Reactions of solid supported reagents and solid supports with alcohols and phenols through their hydroxyl functional group. J. Comb. Chem. (2003) 5, 479-546.

49. Parang K., Preface, Anti-HIV design, Bentham Science Publishers, Hilversum, Current Pharm. Design (2003) 9, 22.

50. Nam N. H., Parang K. Current Drug Targets for Anticancer Drug Discovery. Current Drug Targets (2003), 4, 159-179.

51. Parang K., Cole P. A. Bisubstrate inhibitors of protein kinases. Pharmacology and Therapeutics (2002) 93, 145-157.

52. Parang K. Polymer-supported reagents for methylphosphorylation and phosphorylation of Carbohydrates. Bioorg. Med. Chem. Lett. (2002) 12, 1863-1866.

53. Parang K., Kohn J. A., Saldahna A., Cole P. A. Development of photo-crosslinking reagents for protein kinase-substrate interactions. Febs Letters (2002) 520, 156-160.

54. Parang K., Preface, Anti-HIV design, Bentham Science Publishers, Hilversum, Current Pharm. Design (2002) 8, 8.

55. Parang K., Fournier E. J.-L., Hindsgaul O. A solid phase reagent for the capture phosphorylation of carbohydrate and nucleosides. Org. Lett. (2001) 3, 307-309.

56. Courtney A., Cole, P. A., Parang K., Ablooglu A., Kohanski R. Bisubstrate inhibitors of kinases. PCT Int. Appl. WO 0170770 (2001) 39 pp.

57. Parang K., Till J. H., Ablooglu A. J., Kohanski R. A., Hubbard S. R., Cole P. A. Mechanism-based design of a protein kinase inhibitor. Nature Structural Biology (2001) 8, 37-41.

58. Parang K., Wiebe L. I., Knaus E. E. Novel approaches in designing prodrugs of AZT. Current Medicinal Chemistry (2000) 7, 995-1039.

59. Kim K., Parang K., Lau O. D., Cole P. A. Tyrosine analogs as alternative substrates for protein tyrosine kinase Csk: insights into substrate selectivity and catalytic mechanism. Bioorg. Med. Chem. (2000) 8, 1263-1268.

60. Ablooglu A. J., Till J. K., Kim K., Parang K., Cole P. A., Hubbard S. R., Kohanski R. A. Probing the catalytic mechanism of the insulin receptor kinase with a tetrafluorotyrosine-containing peptide substrate. J. Biol. Chem. (2000) 275, 30394-30398.

61. Parang K., Wiebe L. I., Knaus E. E., Huang J. S., Tyrrell D. L. In vitro anti-hepatitis B virus activities of 5’-O-myristoyl analogue derivatives of 3’-fluoro-2’,3’-dideoxythymidine (FLT) and 3’-azido-2’,3’-dideoxythymidine (AZT). J. Pharm. Pharmaceut. Sci. (1998) 1, 107-113.

62. Parang K., Knaus E. E., Wiebe L. I. Synthesis, in vitro anti-HIV activity, and biological stability of 5’-O-myristoyl analogue derivatives of 3’-fluoro-2’,3’-dideoxythymidine (FLT) as potential prodrugs of FLT. Nucleosides & Nucleotides (1998) 17, 987-1008.

63. Parang K., Wiebe L. I., Knaus E. E. In vivo pharmacokinetic parameters, liver and brain uptake of (±)-3’-azido-2’,3’-dideoxy-5’-O-(2-bromomyristoyl)thymidine as potential prodrug of 3’-azido-3’-deoxythymidine. J. Pharm. Pharmacol. (1998) 50, 989-996.

64. Parang K., Knaus E. E., Wiebe L. I. Synthesis, in vitro anti-HIV structure-activity relationships and stability of 5’-O-myristoyl analogue derivatives of 3’-azido-2’,3’-dideoxythymidine as potential prodrugs of 3’-azido-2’,3’-dideoxythymidine (AZT). Antiviral. Chem. Chemother. (1998) 9, 311-323.

65. Parang, K., Wiebe, L. I., Knaus, E. E. Syntheses and biological evaluation of 5’-O-myristoyl derivatives of thymidine against human immunodeficiency virus (HIV-1). Antiviral. Chem. Chemother. (1997) 8, 417-427.

66. Parang K., Wiebe L. I., Knaus E. E., Huang J. S., Tyrrell D. L., Csizmadia F. In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis viruses. Antiviral Research (1997) 34, 75-90.

67. Parang K., Knaus E. E., Wiebe L. I., Sardari S., Daneshtalab M., Csizmadia F. Synthesis and antifungal activities of myristic acid analogs. Arch. Pharm.-Pharm. Med. Chem. (1996) 329, 475-482.

68. Sharifan A., Parang K., Zorrieh-Amirian H., Nazarinia M., Shafiee A. Synthesis of 1-substituted 1,2,4-triazoles, imidazoles and benzimidazoles. J. Heter. Chem. (1994) 31, 1421-1423.

69. Shafiee A., Parang K., Khazen M., Ghasemian F. Synthesis of substituted 2-(1-methyl-5- nitro-2-imidazolyl)quinolines. J. Heter. Chem. (1992) 29, 1859-1861.

70. Shafiee A., Pirouzzadeh B., Ghasemian F., Parang K. Synthesis of 2-acetyl-1-methyl -5-nitroimidazole. J. Heter. Chem. (1992) 29, 1021-1023.